← Markets

Illumina, Inc.

ILMN · NASDAQ

Market closed$186.65$-3.60 (-1.89%)After hours $186.94 · +0.16%

Key statistics

Previous close$190.25
Open$188.80
Day high$190.25
Day low$184.06
52-week high$196.66
52-week low$88.00
Market cap28.24B
Volume1.25M
Average volume1.85M
P/E ratio37.11
Forward P/E—
EPS5.03
Dividend yield0.00%

Market context

Why it moved

Illumina shares declined as investors engaged in profit-taking ahead of the upcoming Q2 earnings report on July 30, with concerns about competitive pressure from Roche's newly launched Axelios 1 sequencer and notable insider selling activity weighing on a stock that had already surged roughly 44% year-to-date near its 52-week high.

MarketbeatMarketbeatSimplywallAcTikr

What is happening

Recent company-specific developments and publisher coverage.

July 17, 2026Illumina shares rose modestly, partly recovering from the prior session's 3.3% decline triggered by an adverse Munich court ruling that found Illumina and its German subsidiary infringed Element Biosciences' DNA-sequencing imaging patent, ordering an injunction and product recall at Illumina's expense. Helping offset the legal overhang, Illumina announced an expansion of its Billion Cell Atlas program with new AI drug developer partners including Formation Bio, reinforcing its role as core sequencing infrastructure for next-generation therapeutics. Healthcare sector tailwinds from strong earnings beats by UnitedHealth and Abbott also provided a supportive backdrop, even as the broader market navigated tech-led volatility ahead of Illumina's Q2 earnings scheduled for July 30.

1.6564

July 16, 2026Illumina shares fell nearly 2% amid a significant legal setback in Europe, as the Regional Court of Munich I ruled that Illumina infringed Element Biosciences' DNA-sequencing imaging patent, ordering a product injunction and customer recall in Germany at Illumina's expense. The ruling raises fresh concerns about Illumina's IP risk management and European revenue exposure, compounding existing pressure from weak research spending and China headwinds. Canaccord Genuity maintained a Hold rating but raised its price target to $190, while the broader analyst consensus average target of ~$166 implies notable downside from current levels.

-2.1182

July 15, 2026Illumina edged higher, buoyed by a notable analyst upgrade as Canaccord Genuity raised its price target from $140 to $190 while maintaining a Hold rating — a 36% target increase that signals growing confidence in the genomics company's recovery trajectory. The move came on a day when broader markets rebounded on a cooler-than-expected June CPI print (headline inflation fell to 3.5%), helping lift rate-sensitive growth stocks, though the healthcare sector (XLV) faced its own headwinds ahead of major earnings reports from J&J, UnitedHealth, and Abbott.

0.6051

July 14, 2026Illumina closed essentially flat as a pair of analyst price target increases failed to lift sentiment, with both targets implying meaningful downside from current levels — one raised to $165.72 and another to $162.94, suggesting roughly 13-14% downside. The broader backdrop was challenging for healthcare, with the XLV sector ETF slipping amid a risk-off session driven by renewed U.S.-Iran military exchanges that sent oil prices surging and weighed on equities broadly. Adding to the company narrative, Illumina recently named a new chief commercial officer and chief legal officer, signaling continued C-suite rebuilding under its current leadership.

-0.0789

July 11, 2026Illumina fell nearly 2% on Friday, underperforming a broadly mixed but ultimately higher market, as the healthcare sector (XLV) also pulled back modestly from recent record highs. The stock's decline came despite a constructive backdrop: the company confirmed it will report Q2 2026 results on July 30, drawing investor attention ahead of the print. Recent commentary has highlighted Illumina's recovery story — shares are up roughly 46% year-to-date following a multi-year downturn — with the NovaSeq X driving revenue and margin improvement post-GRAIL. Peer activity in diagnostics and life sciences tools also drew attention, as Qiagen surged 11% on buyout interest while DiaSorin rejected a Thermo Fisher bid, keeping M&A themes active in the sector.

-1.8373

July 10, 2026Illumina shares rose sharply, approaching their 52-week high of $196.66, extending a momentum-driven rally fueled by strong Q1 results and an upward revision to full-year EPS guidance. The company also announced two senior leadership appointments — Mike Sullivan as Chief Commercial Officer and Julie Coletti as Chief Legal Officer — signaling continued execution under CEO Jacob Thaysen. A bullish Seeking Alpha piece highlighted Illumina's dominant genomics sequencing moat and NovaSeq X platform catalysts, while a DCF analysis suggested the stock remains ~27% undervalued. The gains came despite renewed U.S.-Iran tensions rattling broader markets, with health care outperforming as a relative safe haven, and Illumina confirming a Q2 earnings call for July 30.

3.1681

July 8, 2026Illumina shares pulled back modestly despite strong Q1 momentum and fresh analyst upgrades, with both Guggenheim and Evercore raising price targets to $200. The stock has surged over 54% since its Q1 beat — where revenues of $1.09B topped estimates by 1.8% — but now faces a new competitive threat as Roche launched the $750K Axelios NGS system targeting Illumina's dominant NovaSeq X franchise. A recent board addition of Eli Lilly's Chief Scientific Officer signals a strategic push into clinical genomics, while the broader healthcare sector continues to outperform tech amid ongoing rotation.

-1.3225

July 7, 2026Illumina advanced nearly 3%, touching a new 52-week high of $195.09, as bullish analyst activity and a sustained healthcare sector rally fueled investor enthusiasm. Guggenheim raised its price target to $200 from $180, while the broader healthcare sector posted a second consecutive week of market-leading gains per XLV performance. Competitive headwinds from Roche's new $750,000 Axelios NGS system targeting Illumina's flagship NovaSeq X franchise tempered some optimism, though Barclays also recently lifted its target to $145—even while maintaining an Underweight—and the appointment of Eli Lilly's Chief Scientific Officer to Illumina's board signals a strategic pivot toward high-growth clinical genomics.

2.9945

TIKR.com · July 19, 2026Wall Street Just Pushed Illumina Targets to $200. Here’s Where the Stock Could Goad-hoc-news.de · July 19, 2026Illumina stock steadies as investors weigh going concern warning and turnaround planSimply Wall Street · July 16, 2026Illumina (ILMN) Expands Billion Cell Atlas Alliance With New AI Drug Discovery MembersInvesting News Network · July 16, 2026Illumina expands Billion Cell Atlas program with new AI drug developersPR Newswire · July 16, 2026Illumina expands Billion Cell Atlas program with new AI drug developersReuters · June 29, 2026Roche takes aim at Illumina's dominance with new gene sequencing machinePR Newswire · April 30, 2026Illumina Reports Financial Results for First Quarter of Fiscal Year 2026PR Newswire · February 5, 2026Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025
Benzinga · July 17, 2026Leerink Partners Maintains Outperform on Illumina, Raises Price Target to $210
Benzinga · July 14, 2026Canaccord Genuity Maintains Hold on Illumina, Raises Price Target to $190
Mt Newswire · July 9, 2026Align Technology Chief Legal Officer Julie Coletti to Leave for Illumina
Benzinga · July 1, 2026Piper Sandler Maintains Overweight on Illumina, Raises Price Target to $200
Benzinga · June 29, 2026Guggenheim Maintains Buy on Illumina, Raises Price Target to $200
Benzinga · June 26, 2026Bernstein Reinstates Market Perform on Illumina, Announces $185 Price Target
Benzinga · June 24, 2026Barclays Maintains Underweight on Illumina, Raises Price Target to $145
Benzinga · June 10, 2026JP Morgan Upgrades Illumina to Overweight, Raises Price Target to $185

Peers

S&P 500SPX · $7,457.69-1.01%Thermo Fisher Scientific Inc.TMO · $532.48-1.97%Danaher CorporationDHR · $203.83-0.58%Agilent Technologies, Inc.A · $131.46-3.41%Qiagen N.V.QGEN · $41.15-0.87%Waters CorporationWAT · $368.98-2.44%Pacific Biosciences of California, Inc.PACB · $1.44-3.36%Oxford Nanopore Technologies plcONT.L · 112.30-3.11%10x Genomics, Inc.TXG · $43.74-1.65%Twist Bioscience CorporationTWST · $93.85+2.87%Natera, Inc.NTRA · $271.39+0.58%Guardant Health, Inc.GH · $155.87+0.56%